Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

OptiNose stock price, quote, forecast and news

OPTN
US68404V1008
A2H5PR

Price

0.72
Today +/-
-0.04
Today %
-5.62 %
P

OptiNose stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the OptiNose stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the OptiNose stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the OptiNose stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze OptiNose's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

OptiNose Stock Price History

DateOptiNose Price
9/23/20240.72 undefined
9/20/20240.76 undefined
9/19/20240.80 undefined
9/18/20240.85 undefined
9/17/20240.86 undefined
9/16/20240.89 undefined
9/13/20240.91 undefined
9/12/20240.94 undefined
9/11/20240.92 undefined
9/10/20240.93 undefined
9/9/20240.96 undefined
9/6/20240.95 undefined
9/5/20240.98 undefined
9/4/20240.99 undefined
9/3/20241.00 undefined
8/30/20241.04 undefined
8/29/20241.07 undefined
8/28/20241.03 undefined
8/27/20241.03 undefined
8/26/20240.93 undefined

OptiNose Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into OptiNose, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by OptiNose from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects OptiNose’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of OptiNose. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into OptiNose’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing OptiNose’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on OptiNose’s growth potential.

OptiNose Revenue, EBIT and net profit per share

DateOptiNose RevenueOptiNose EBITOptiNose Net Income
2030e357 M undefined188.19 M undefined230.69 M undefined
2029e379.19 M undefined161.57 M undefined98.43 M undefined
2028e348.66 M undefined144.32 M undefined92.28 M undefined
2027e239.29 M undefined71.5 M undefined50.75 M undefined
2026e170.78 M undefined28.75 M undefined19.99 M undefined
2025e131.62 M undefined9.63 M undefined-14.35 M undefined
2024e88.33 M undefined-13.01 M undefined-34.99 M undefined
202370.99 M undefined-22.75 M undefined-35.48 M undefined
202276.28 M undefined-55.9 M undefined-74.83 M undefined
202174.65 M undefined-66.45 M undefined-82.3 M undefined
202049.12 M undefined-87.22 M undefined-99.79 M undefined
201934.63 M undefined-95.6 M undefined-110.05 M undefined
20187.07 M undefined-100.24 M undefined-106.66 M undefined
20170 undefined-48.53 M undefined-61.97 M undefined
201647.5 M undefined25.32 M undefined1.62 M undefined
201590,000 undefined-28.08 M undefined-40.38 M undefined

OptiNose Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
04707344974767088131170239348379357
----385.7144.1251.022.70-7.8925.7148.8629.7740.5945.618.91-5.80
---71.4385.2983.6787.8488.1688.57-------
000529416567620000000
-2825-48-100-95-87-66-55-22-1392871144161188
-53.19--1,428.57-279.41-177.55-89.19-72.37-31.43-14.776.8716.4729.7141.3842.4852.66
-401-61-106-110-99-82-74-35-34-1419509298230
--102.50-6,200.0073.773.77-10.00-17.17-9.76-52.70-2.86-58.82-235.71163.1684.006.52134.69
35.3935.3937.839.7741.8848.2856.8585.9112.080000000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The OptiNose Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the OptiNose is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (k)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201520162017201820192020202120222023
                 
15.236.8234.9201147.1144.2110.594.273.68
0.40.402.613.823.435.433.919.93
020000000
0027.13.5911.89.48.05
0.21.51.32.23.642.62.93.67
15.840.7238.2212.9168180.6160.3140.4105.33
0.20.32.63.94.485.43.22.29
000000000
000000000
000000000
000000000
0600400200200200300500109
0.20.934.14.68.25.73.72.4
1641.6241.2217172.6188.8166144.1107.73
                 
155.1168.20000.10.10.10.11
00365.8436.6489.6534.6588.3628.2633.74
-161.3-151.1-211.3-317.9-428-527.8-610.1-684.9-720.38
-0.1-0.1-0.1-0.10-0.1-0.1-0.1-0.08
000000000
-6.317154.4118.661.66.8-21.8-56.7-86.61
3.53.45.97.13.65.585.33.89
3.62.58.718.432.546.751.244.942.41
0020020000000
0000000128.6130.23
000000000
7.15.914.825.736.152.259.2178.8176.52
14.515.371.972.574.5125.2126.400
000000000
0.73.400.20.44.72.222.117.81
15.218.771.972.774.9129.9128.622.117.81
22.324.686.798.4111182.1187.8200.9194.34
1641.6241.1217172.6188.9166144.2107.73
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of OptiNose provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand OptiNose's financial health and stability.

Assets

OptiNose's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that OptiNose must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of OptiNose after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into OptiNose's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201520162017201820192020202120222023
-2822-48-106-110-99-82-74-35
00001,0001,000000
000000000
-1-27500-6-511
111017272221217
0008811141513
000000000
-2821-35-91-90-86-76-67-20
00-2-100000
00-2-100000
000000000
000000000
140750-2-3000
5017466458843510
19023659378343510
---13.00-6.00-5.00----
000000000
-921198-33-53-2-33-16-20
-28.7921.5-38.09-93.51-91.38-86.76-77.11-67.71-20.86
000000000

OptiNose stock margins

The OptiNose margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OptiNose. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OptiNose.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the OptiNose's sales revenue. A higher gross margin percentage indicates that the OptiNose retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the OptiNose's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the OptiNose's total revenue generated. When comparing the revenue margin year over year, investors can gauge the OptiNose's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the OptiNose. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the OptiNose's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

OptiNose Margin History

OptiNose Gross marginOptiNose Profit marginOptiNose EBIT marginOptiNose Profit margin
2030e87.84 %52.71 %64.62 %
2029e87.84 %42.61 %25.96 %
2028e87.84 %41.39 %26.47 %
2027e87.84 %29.88 %21.21 %
2026e87.84 %16.84 %11.71 %
2025e87.84 %7.32 %-10.91 %
2024e87.84 %-14.73 %-39.61 %
202387.84 %-32.05 %-49.99 %
202287.85 %-73.28 %-98.1 %
202187.74 %-89.02 %-110.25 %
202084.69 %-177.57 %-203.16 %
201984.72 %-276.06 %-317.79 %
201877.51 %-1,417.82 %-1,508.63 %
201787.84 %0 %0 %
201687.84 %53.31 %3.41 %
201587.84 %-31,200 %-44,866.67 %

OptiNose Stock Sales Revenue, EBIT, Earnings per Share

The OptiNose earnings per share therefore indicates how much revenue OptiNose has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue OptiNose earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates OptiNose's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of OptiNose’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating OptiNose's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

OptiNose Revenue, EBIT and net profit per share

DateOptiNose Sales per ShareOptiNose EBIT per shareOptiNose Earnings per Share
2030e2.37 undefined0 undefined1.53 undefined
2029e2.51 undefined0 undefined0.65 undefined
2028e2.31 undefined0 undefined0.61 undefined
2027e1.59 undefined0 undefined0.34 undefined
2026e1.13 undefined0 undefined0.13 undefined
2025e0.87 undefined0 undefined-0.1 undefined
2024e0.59 undefined0 undefined-0.23 undefined
20230.63 undefined-0.2 undefined-0.32 undefined
20220.89 undefined-0.65 undefined-0.87 undefined
20211.31 undefined-1.17 undefined-1.45 undefined
20201.02 undefined-1.81 undefined-2.07 undefined
20190.83 undefined-2.28 undefined-2.63 undefined
20180.18 undefined-2.52 undefined-2.68 undefined
20170 undefined-1.28 undefined-1.64 undefined
20161.34 undefined0.72 undefined0.05 undefined
20150 undefined-0.79 undefined-1.14 undefined

OptiNose business model

OptiNose Inc is a leading company in the field of nasal therapy, focused on improving the quality of life for patients with various upper respiratory tract conditions. The company was founded in 2010 and is headquartered in Yardley, Pennsylvania, USA. OptiNose developed a new therapy approach for nasal diseases based on the technology of the "Exhalation platform." This technology utilizes the patient's natural exhaling to deliver medication deep into the nasal and sinus regions where it is most needed. OptiNose Inc has patented and further developed this technology in 2009. The company's business model is based on the development and marketing of medications and medical devices that utilize the Exhalation platform technology. This innovative technology can be used to treat various upper respiratory conditions and complaints, including chronic sinusitis, allergic rhinitis, migraines, and other headache disorders. OptiNose Inc currently operates in two main business areas: therapeutic products and diagnostic and monitoring devices. Therapeutic products include various medications delivered through the Exhalation platform technology, as well as accessories such as spray devices. The diagnostic and monitoring devices include various products aimed at testing different diseases affecting the upper respiratory tract. One of OptiNose Inc's most well-known products is the XHANCE nebulizer, used to deliver inhaled medications deep into patient's nasal passages. Other important products include the OPTIMIST system, used for medication delivery to treat sinus and nasal conditions, and the Sinuva sinus implant, used for the treatment of nasal cavity narrowing and polyps. In addition, OptiNose Inc works closely with various research and development partners to develop new diagnostic and therapeutic approaches for upper respiratory tract diseases. In this way, the company is always seeking new opportunities to improve the quality of life for patients with these conditions. OptiNose Inc is a dynamic and innovative company focused on the development and marketing of advanced nasal therapy solutions. With modern technology, highly qualified personnel, and a strong focus on the needs of its patients, it will certainly continue to achieve significant success in the future. OptiNose is one of the most popular companies on Eulerpool.com.

OptiNose SWOT Analysis

Strengths

OptiNose Inc. holds a strong position in the market as a provider of innovative drug delivery solutions. Its patented technology, called Exhalation Delivery Systems (EDS), offers unique benefits over traditional nasal sprays, providing efficient and targeted delivery of medications. This market leadership gives OptiNose a competitive edge and allows it to differentiate itself from competitors.

OptiNose has a robust product pipeline, with multiple potential drug candidates in various stages of development. This diverse portfolio reduces the company's reliance on a single product and enhances its ability to address different medical conditions. The strong product pipeline positions OptiNose for future growth and expansion into new therapeutic areas.

Weaknesses

Despite its strong market position, OptiNose is heavily dependent on a limited number of products for its revenue generation. This concentration of revenue increases the company's vulnerability to the performance of these specific products, making it susceptible to market fluctuations and competitive pressures. Diversification of product offerings could mitigate this weakness.

OptiNose operates in a highly competitive market with well-established players. As a relatively smaller company, it faces challenges in terms of market penetration and gaining significant market share. Increased efforts in marketing and distribution, as well as strong partnerships, could help OptiNose expand its market presence.

Opportunities

The healthcare industry is witnessing an increasing preference for non-invasive drug delivery systems due to their convenience and improved patient compliance. OptiNose, with its advanced Exhalation Delivery Systems, is well-positioned to capitalize on this trend and cater to the growing demand for such solutions. This presents a significant growth opportunity for the company.

OptiNose currently operates primarily in the United States. The company has an opportunity to expand its market reach by entering new geographical markets and establishing a global presence. With approvals and partnerships in other countries, OptiNose can tap into untapped markets, diversify its revenue streams, and increase its market share.

Threats

The drug delivery industry is highly competitive, with numerous players offering alternative solutions. OptiNose faces the threat of aggressive competition, which may impact its market share and pricing power. Continuous innovation, strong intellectual property management, and effective marketing strategies are vital to mitigate this threat and maintain a competitive advantage.

Compliance with the complex and evolving regulatory landscape is a significant challenge for OptiNose. Changes in regulations, delays in approvals, and potential safety concerns may hinder product launches or restrict the company's ability to operate in certain markets. Robust regulatory strategies and close collaborations with regulatory authorities are essential to navigate these challenges successfully.

OptiNose Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

OptiNose Revenue by Segment

Segmente202320222021202020192018
Net product revenues70.99 M USD76.28 M USD73.65 M USD48.37 M USD30.4 M USD-
Licensing revenues--1 M USD750,000 USD4.23 M USD-
License-----70,000 USD

OptiNose Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

OptiNose historical P/E ratio, EBIT, and P/S ratio.

OptiNose shares outstanding

The number of shares was OptiNose in 2023 — This indicates how many shares 112.08 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue OptiNose earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates OptiNose's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of OptiNose’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating OptiNose's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for OptiNose.

OptiNose latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.08 -0.05  (36.55 %)2024 Q2
3/31/2024-0.11 -0.12  (-9.39 %)2024 Q1
12/31/2023-0.1 -0.09  (6.44 %)2023 Q4
9/30/2023-0.1 -0.08  (16.84 %)2023 Q3
6/30/2023-0.11 0.02  (118.07 %)2023 Q2
3/31/2023-0.14 -0.17  (-19.63 %)2023 Q1
12/31/2022-0.18 -0.17  (4.6 %)2022 Q4
9/30/2022-0.19 -0.18  (4.61 %)2022 Q3
6/30/2022-0.24 -0.23  (6.05 %)2022 Q2
3/31/2022-0.28 -0.31  (-12.56 %)2022 Q1
1
2
3

Eulerpool ESG Scorecard© for the OptiNose stock

Eulerpool World ESG Rating (EESG©)

36/ 100

🌱 Environment

38

👫 Social

47

🏛️ Governance

23

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

OptiNose list of shareholders

%
Name
Stocks
Change
Date
9.72738 % Fidelity Management & Research Company LLC14,666,941-181,92912/31/2023
9.68647 % MVM Partners LLP14,605,263012/31/2023
5.86281 % Great Point Partners, LLC8,839,939012/31/2023
4.83486 % Kruttschnitt (Theodore H III)7,290,000474,21112/31/2023
4.49586 % Acorn Bioventures L.P.6,778,851407,38812/31/2023
3.24020 % Rosalind Advisors, Inc.4,885,580-1,549,42012/31/2023
2.77205 % The Vanguard Group, Inc.4,179,704358,23112/31/2023
2.71152 % BlackRock Institutional Trust Company, N.A.4,088,427273,64412/31/2023
2.68280 % Bleichroeder LP4,045,132012/31/2023
2.58604 % Kingdon Capital Management, L.L.C.3,899,237200,00012/31/2023
1
2
3
4
5
...
10

OptiNose Executives and Management Board

Dr. Ramy Mahmoud58
OptiNose Chief Executive Officer, Director (since 2010)
Compensation 1.14 M
Mr. Michael Marino47
OptiNose Chief Legal Officer, Corporate Secretary
Compensation 996,694
Mr. R. John Fletcher77
OptiNose Independent Chairman of the Board
Compensation 128,276
Ms. Sandra Helton73
OptiNose Independent Director
Compensation 101,423
Mr. Wilhelmus Groenhuysen65
OptiNose Independent Director
Compensation 98,923
1
2
3

OptiNose Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Flex Ltd Stock
Flex Ltd
SupplierCustomer0,580,590,47-0,140,22-0,51
AmerisourceBergen Stock
AmerisourceBergen
SupplierCustomer0,38-0,23-0,040,47-0,29-0,72
Cardinal Health Stock
Cardinal Health
SupplierCustomer0,350,770,110,420,230,03
McKesson Stock
McKesson
SupplierCustomer0,33-0,75-0,450,38-0,41-0,72
1

Most common questions regarding OptiNose

What values and corporate philosophy does OptiNose represent?

OptiNose Inc represents a strong commitment to improving patient care and quality of life through innovative nasal drug delivery solutions. The company's corporate philosophy is centered around delivering effective and convenient treatment options for patients suffering from various nasal conditions. OptiNose Inc focuses on developing advanced technology, such as their patented exhalation delivery system, which optimizes drug deposition in the nasal cavity. This dedication to innovation and patient-centric approach reflects OptiNose Inc's core values of excellence, integrity, and compassion. Through their unique delivery platform, OptiNose Inc aims to transform the way nasal medications are administered, providing better outcomes for patients worldwide.

In which countries and regions is OptiNose primarily present?

OptiNose Inc is primarily present in the United States.

What significant milestones has the company OptiNose achieved?

OptiNose Inc has achieved significant milestones since its inception. Firstly, the company successfully developed and gained FDA approval for its innovative drug delivery technology named XHANCE. This groundbreaking intranasal device provides a more efficient and targeted treatment for chronic nasal inflammation. Additionally, OptiNose Inc has expanded its portfolio through partnerships and collaborations, allowing for the development of new therapies. The company's commitment to research and innovation has resulted in improved patient outcomes and positioned OptiNose Inc as a leader in the healthcare industry. OptiNose Inc continues to strive for further advancements in drug delivery and therapeutic options.

What is the history and background of the company OptiNose?

OptiNose Inc, a pharmaceutical company, was founded in 2010 and is headquartered in Pennsylvania, United States. The company specializes in developing innovative therapeutics that utilize their patented Breath Powered® drug delivery system. OptiNose aims to enhance drug delivery to the upper nasal cavity, providing more effective and targeted treatments for patients. They have a strong focus on respiratory conditions and have successfully commercialized several products for conditions like chronic rhinosinusitis with nasal polyps. OptiNose's commitment to innovative drug delivery technology and dedication to improving patient outcomes has established them as a leading player in the pharmaceutical industry.

Who are the main competitors of OptiNose in the market?

The main competitors of OptiNose Inc in the market are pharmaceutical companies that also develop and commercialize intranasal drug delivery solutions. OptiNose faces competition from companies such as GlaxoSmithKline (GSK), AstraZeneca, and Pfizer, who offer similar products for treating various nasal and sinus conditions. However, OptiNose differentiates itself through its unique patented Exhalation Delivery Systems (EDS), which provide higher drug deposition and improved patient outcomes. OptiNose's focus on innovation and its commitment to improving the lives of patients make it a strong contender in the competitive intranasal drug delivery market.

In which industries is OptiNose primarily active?

OptiNose Inc is primarily active in the pharmaceutical industry.

What is the business model of OptiNose?

The business model of OptiNose Inc revolves around developing and commercializing innovative drug delivery solutions. OptiNose specializes in creating and marketing products that utilize its unique delivery technology, called the Exhalation Delivery System (EDS), to efficiently and effectively deliver drugs to the nasal and sinus cavities. By leveraging this technology, OptiNose aims to provide patients with improved treatment options for various conditions, including chronic rhinosinusitis, migraines, and other nasal inflammatory diseases. Through strategic partnerships and collaborations, OptiNose strives to optimize its drug delivery platform and expand its product portfolio to cater to a wide range of medical needs.

What is the P/E ratio of OptiNose 2024?

The OptiNose P/E ratio is -2.31.

What is the P/S ratio of OptiNose 2024?

The OptiNose P/S ratio is 0.91.

What is the AlleAktien quality score of OptiNose?

The AlleAktien quality score for OptiNose is 5/10.

What is the revenue of OptiNose 2024?

The expected OptiNose revenue is 88.33 M USD.

How high is the profit of OptiNose 2024?

The expected OptiNose profit is -34.99 M USD.

What is the business model of OptiNose

OptiNose Inc. is a pharmaceutical company based in Pennsylvania, USA. The company is known for its unique technology used in the treatment of respiratory diseases such as chronic sinusitis, migraines, and cluster headaches. OptiNose's main focus is the development and marketing of cutting-edge respiratory therapy products. The company aims to provide innovative nasal medication solutions to patients and healthcare providers for effective treatment options. OptiNose is involved in medication development and marketing, technology licensing, and partnerships with other companies for distribution. The company's patented Exhalation Delivery System technology allows for the administration of medications in small particles that can be absorbed by the nasal mucosa. OptiNose is a rapidly growing company with a strong financial position, investing in research and development as well as distribution activities. They aspire to differentiate themselves in the competitive market and solidify their position as a market leader by introducing new medications. In summary, OptiNose offers a unique technology platform for nasal medication delivery, enabling the development and distribution of cutting-edge respiratory therapy products.

What is the OptiNose dividend?

OptiNose pays a dividend of 0 USD distributed over payouts per year.

How often does OptiNose pay dividends?

The dividend cannot currently be calculated for OptiNose or the company does not pay out a dividend.

What is the OptiNose ISIN?

The ISIN of OptiNose is US68404V1008.

What is the OptiNose WKN?

The WKN of OptiNose is A2H5PR.

What is the OptiNose ticker?

The ticker of OptiNose is OPTN.

How much dividend does OptiNose pay?

Over the past 12 months, OptiNose paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, OptiNose is expected to pay a dividend of 0 USD.

What is the dividend yield of OptiNose?

The current dividend yield of OptiNose is .

When does OptiNose pay dividends?

OptiNose pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of OptiNose?

OptiNose paid dividends every year for the past 0 years.

What is the dividend of OptiNose?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is OptiNose located?

OptiNose is assigned to the 'Health' sector.

Wann musste ich die Aktien von OptiNose kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of OptiNose from 9/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/24/2024.

When did OptiNose pay the last dividend?

The last dividend was paid out on 9/24/2024.

What was the dividend of OptiNose in the year 2023?

In the year 2023, OptiNose distributed 0 USD as dividends.

In which currency does OptiNose pay out the dividend?

The dividends of OptiNose are distributed in USD.

All fundamentals about OptiNose

Our stock analysis for OptiNose Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OptiNose Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.